Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
Go back to Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia| Merck & Co. (NYSE: MRK) | Delayed: 146.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.87 | 52 Week High | $65.46 | |||
| Open | $146.87 | 52 Week Low | $47.97 | |||
| Day High | $146.87 | P/E | 99.91 | |||
| Day Low | $146.87 | EPS | $1.47 | |||
| Volume | 4,977 | |||||
